Dr. Fabian M. Kausche, M.S. Dr.med.vet
Pet Products and Services
Dr. Kausche advises Bessemer Investors on investments in the animal health sector. Dr. Kausche advised Bessemer Investors on its partnership with Pet Flavors and serves as a member of its board of directors.
Additionally, Dr. Kausche is a member of the board of Sequent Scientific/Alivira a global India-based company developing and marketing high quality generics. He is Chairman of the Board of PetMedix, a start-up company in Cambridge, UK developing monoclonal antibodies for companion animals. He also works as scientific advisor for Rejuvenate Bio a California-based startup that develops modern gene therapies for companion animals and is a member of the board of trustees of GALVmed a UK-based charity developing medicines for small holder farmers in sub-Saharan Africa and Asia.
Dr. Kausche has several decades of senior executive experience in the animal and human health industries in both biological and pharmaceutical research and development.
He held subsequent positions as Global Head of Research & Development for three of the top eight global Animal Health companies: Novartis Animal Health, Merial, and Boehringer Ingelheim Animal Health. Before leaving Boehringer Ingelheim Animal Health in December 2018, he led the post-merger integration of the largest R&D organization in the Animal Health industry with more than 1,200 scientist and support staff. In addition to his extensive Animal Health R&D experience, he gained additional expertise in the human health space as head of R&D for Novartis Consumer Health. Prior to that, he also successfully led a companion animal sales force for Novartis Animal Health.
A native of Germany, Dr. Kausche received a veterinary degree from the Hannover Veterinary School. He subsequently completed a Master of Science degree at Iowa State University. Following the completion of the M.S. degree, Dr. Kausche returned to Europe and took part in a research program that led him to receiving the German PhD (Dr.med.vet.) in a combination program between the Hannover Medical and Veterinary Schools. Having completed the Advanced Management Program in 2005, he is also an alumnus of Harvard Business School